US Stock MarketDetailed Quotes
FOLD Amicus Therapeutics
- 9.660
- +0.160+1.68%
Close Nov 22 16:00 ET
- 9.880
- +0.220+2.28%
Post 18:53 ET
2.89BMarket Cap-28411P/E (TTM)
9.780High9.460Low1.93MVolume9.510Open9.500Pre Close18.57MTurnover0.79%Turnover RatioLossP/E (Static)298.81MShares14.57052wk High16.15P/B2.37BFloat Cap9.02052wk Low--Dividend TTM245.30MShs Float25.390Historical High--Div YieldTTM3.37%Amplitude1.765Historical Low9.646Avg Price1Lot Size
Amicus Therapeutics Stock Forum
Sign in to post a comment
$Amicus Therapeutics (FOLD.US)$
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk
3
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
8
Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.
1
Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.
$Amicus Therapeutics (FOLD.US)$ FDA approval 🚀🙏🏻
$Amicus Therapeutics (FOLD.US)$ News halt...... watching
1
$Amicus Therapeutics (FOLD.US)$ Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.
$Amicus Therapeutics (FOLD.US)$ Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Tonyco OP :
Tonyco OP :
Tonyco OP :